INFORME PUBLICITÁRIO

ANVISA ACHIEVED GREAT ADVANCEMENTS TO THE HEALTH OF BRAZILIAN PATIENTS

The Brazilian Health Surveillance Agency (ANVISA)

becomes the first regulatory agency in the Southern

Hemisphere to integrate the Management

Committee of the International Council for

Harmonization (ICH), a forum that brings together

world authorities that define the alignment of health

regulations for medicines and the pharmaceutical

industry.

As a member of this important Committee, ANVISA

is in line with the Brazilian Federal Government’s

agenda raising the countries standards and aligning

with prime-markets, promoting the harmonization of

the regulatory framework to international standards,

boosting trade between countries and promoting

economic growth, as well as broadening concrete

possibilities for Brazil ascensions to International

Forums and organizations.

This effort will bring more investments, jobs, income

and relevant innovations for health in Brazil.

For the Regulatory Agency, it means giving voice

to the country in defining international rules for

medicines and pharmaceutical research. It puts Brazil

in the same level of discussion for regulations of the

United States, the European Union, Japan, Canada,

Switzerland, South Korea, China and Singapore, ICH’s

member nations.

We congratulate ANVISA’s technical team and its

professionals for the modern and results-focused

agenda and the continuous seek for regulatory

convergence, aligning global standards while

maintaining ANVISA’s regulatory independence.

ANVISA’s performance at ICH will translate into greater access to modern therapies and faster drug registration.

An important step for Health in Brazil.

This initiative brings hope and new perspectives to thousands of Brazilian patients.